Clinical study validates capacity of ABB C1™ to stimulate trained immunity
The following article, published in Nutrients journal, describes a clinical study which investigated the effect of ABB C1™ on volunteers receiving flu and COVID-19 vaccines: "Effect and Tolerability of a Nutritional Supplement Based on a Synergistic Combination of β-Glucans and Selenium- and Zinc-Enriched Saccharomyces cerevisiae (ABB C1®) in Volunteers Receiving the Influenza or the COVID-19 Vaccine"
The randomised, double-blind, placebo-controlled study was conducted with 72 volunteers who were given either ABB C1™ or a placebo following vaccination against flu or COVID-19.
Results showed greater increases in the immune response in subjects treated with ABB C1™ versus those receiving the placebo. The ABB C1™ group showed higher levels of key immune cells and antibodies as well as of selenium and zinc. Furthermore, no serious adverse events or tolerance issues related to ABB C1™ were reported.
The study indicates that ABB C1™ improves trained immunity, providing a more specific and protective defence system than standard immune boosters.